Global Cellular Health Testing Market to Reach $4.2 Billion by 2027
Amid the COVID-19 crisis, the global market for Cellular Health Testing estimated at US$2.4 Billion in the year 2020, is projected to reach a revised size of US$4.2 Billion by 2027, growing at aCAGR of 8.5% over the period 2020-2027. Single-Test Panels, one of the segments analyzed in the report, is projected to record 7.4% CAGR and reach US$2.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Multi-Test Panels segment is readjusted to a revised 10.3% CAGR for the next 7-year period.
The U.S. Market is Estimated at $695.6 Million, While China is Forecast to Grow at 8% CAGR
The Cellular Health Testing market in the U.S. is estimated at US$695.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$729.1 Million by the year 2027 trailing a CAGR of 8.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8% and 7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7% CAGR.We bring years of research experience to this 9th edition of our report. The 223-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.Competitors identified in this market include, among others,
- Bio-Reference Laboratories, Inc.
- Cell Science Systems Corp.
- Cleveland Heartlab, Inc.
- Dna Labs India
- Genova Diagnostics
- Immundiagnostik AG
- Laboratory Corporation of America Holdings
- Life Length
- Quest Diagnostics, Inc.
- Repeat Diagnostics Inc. (Repeat Dx)
- Segterra, Inc.
- SpectraCell Laboratories, Inc.
- Telomere Diagnostics, Inc. (Tdx)
- Zimetry LLC